Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 Vaccination.
Stacey WolfsonEric S KimPublished in: Radiology (2022)
A 50-year-old woman with persistent axillary lymphadenopathy 17 weeks following COVID-19 vaccination was ultimately diagnosed with biopsy-proven benign reactive lymphadenopathy. In contrast, a 60-year-old woman with axillary lymphadenopathy and concurrent suspicious breast findings 9 weeks following COVID-19 vaccination was ultimately diagnosed with biopsy-proven metastatic breast carcinoma. This article reviews the current guidelines regarding breast cancer screening and management of axillary lymphadenopathy in the setting of COVID-19 vaccination.
Keyphrases
- fine needle aspiration
- ultrasound guided
- coronavirus disease
- sars cov
- lymph node
- sentinel lymph node
- neoadjuvant chemotherapy
- squamous cell carcinoma
- respiratory syndrome coronavirus
- magnetic resonance
- small cell lung cancer
- randomized controlled trial
- locally advanced
- magnetic resonance imaging
- early stage
- contrast enhanced